Renal cysts, renal cancer and von Hippel-Lindau disease  by Neumann, Hartmut P.H. & Zbar, Berton
Kidney International, Vol. 51 (1997), pp. 16—26
EDITORIAL REVIEW
Renal cysts, renal cancer and von Hippel-Lindau disease
Renal cysts and renal cancer (Fig. I and Table 1), usually occur
sporadically but are typical findings in von Hippel-Lindau disease
(VHL) and are considered cornerstones among the clinical crite-
ria for the diagnosis of this condition [1—3]. Although epidemio-
logical studies have revealed a prevalence of 1:30,000 to 1:50,000
[4—61, this disease is seen rarely by the nephrologist or urologist.
The goals of this review are to describe the clinical characteristics
of VHL and to present current knowledge of the genetic basis of
VHL.
History
In 1904 and 1911, Eugen von Hippel, a German ophthalmolo-
gist (1867—1938), published his classical clinical and histological
descriptions of retinal angiomatosis [7, 8]. One of his patients was
later shown to have renal cancer [9]. In 1926, Arvid Lindau, a
Swedish pathologist (1892—1952), published his studies on a large
series of cystic cerebellar tumors [10]. He provided with convinc-
ing arguments that both retinal and cerebellar lesions are of the
same origin, and also noted renal cysts and renal cancer in four of
his cases. Lindau considered a familiar predisposition for the
disease.
Clinical criteria for diagnosis of YLIL
VHL is an inherited illness, transmitted as an autosomal
dominant trait. Individuals who inherit a mutant VHL gene are
predisposed to develop hemangioblastomas of the cerebellum,
brain stem and spinal cord, retinal angiomas, renal cysts and renal
cancers, pancreatic cysts and pancreatic tumors, pheochromocy-
tomas, and epididymal cystadenomas (Table 1) [11. However, (i)
isolated cases of VHL, and (ii) small families with affected
individuals showing only one feature, or frequently, only visceral
lesions, require more specific diagnostic criteria [2]. The diagnosis
of VHL in a member of a family with VHL can be made if that
individal develops any one of the cardinal manifestations of the
disease (except renal cysts which occur frequently in the normal
population). The diagnosis of VHL in an individual without a
family history of the disease requires at least two of the cardinal
disease manifestations which must include either retinal or central
nervous system involvement. Some families that do not meet these
clinical criteria have been shown to have germline mutations in
the VHL gene [11]. Such families should be considered to have
VHL and he managed like typical VHL families.
Kidney involvement in VHL
Renal involvement in VHL is characterized by multiple, bilat-
eral renal cell carcinomas (RCC) and renal cysts. The mean age at
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presentation is 35 to 40 years [2, 3, 12, 131. The youngest reported
patient was 16 years old [141. In VHL, men and women are
equally affected with RCC in contrast to the male predominance
in sporadic RCC [15]. The clinical course of RCC in VHL is
characterized by metastases to the liver, lungs and bones. RCC
appears to account for about 50% of deaths in VHL [31.
RCC may present with hematuria or with back pain (Fig. I).
Usually, renal cancer in VHL is detected as an incidental finding
during CT or ultrasound examination requested for other reasons,
or when VHL families are screened for occult kidney disease
(Figs. 2 and 3).
The histopathology of renal tumors is clear cell carcinoma (Fig.
4) [12, 16]. Careful macroscopic examination of cystic renal
lesions show a typical epithelium, or even small foci of carcinoma.
Because of these findings, renal cysts have been proposed to be
the cancer-predisposing lesion in VHL-associated RCC [17, 181.
The clear cell renal carcinomas found in VHL are distinct from
the tumors found in hereditary papillary renal carcinoma. Al-
though RCC can metastasize to the central nervous system, a
tumor in the central nervous system in a patient with VHL is likely
to be a hemangioblastoma, not a metastasis from a clear cell renal
carcinoma [19]. Immunohistochemistry using epithelial markers
may be useful in distinguishing RCC metastases from central
nervous system hemangioblastomas [20—22].
VHL can be considered among the conditions associated with
cystic kidney disease (Table 3). The typical lesion in the kidney of
a VHL patient is several renal cysts, although, rarely, the kidney
may have large numbers of renal cysts simulation the appearance
of polycystic kidney disease; deterioration of renal function due to
cystic kidney disease has been reported in VHL, but is exceptional
[23].
Differential diagnosis
The differential diagnosis of VHL-associated renal lesions
includes a number of hereditary and non-hereditary conditions
summarized in Table 3. Autosomal dominant polycystic kidney
disease (ADPKD), like VHL affects both sexes with a similar
mean age (38.5 years, unpublished Freiburg ADPKD study) at
presentation. Kidney involvement in VHL is characterized by a
few bilateral cysts, RCC, normal kidney shape, normotension and
normal renal function. ADPKD is associated with secondary
hypertension, chronic renal failure and innumerable cysts scat-
tered throughout the parenchyma, with enlargement and alter-
ation of the shape of the kidneys. Cyst infection, a frequent
finding in ADPKD, does not occur in VHL. RCC is not generally
considered a component feature of ADPKD, but has been
coincidentally reported rarely [241. Extrarenal manifestations of
both syndromes occur in several organs. Type and pattern,
however, differ considerably. Cysts in the liver are frequent in
ADPKD, but rare in VHL (Table 1). Pancreatic cysts are rare in
ADPKD, but can be numerous and scattered through the pan-
creas in VHL (Fig. 5) [25]. The central nervous system in ADPKD
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Table 1. Frequent and rare lesions in von Hippel-Lindau syndrome
Fig. 1. Symptomatic carcinoma of the left kidney (7 X 5 X 5 cm) in a
40-year-old female VHL patient (abdominal CT scan). Nephrectomy spec-
imen disclosed only one tumor and no cysts; note two cystic, in part solid
lesions of the contralateral kidney (arrows). A. The patient refused regular
follow-up and was admitted 10 years later, because of hematuria, and
showed a large contralateral renal carcinoma (B).
is affected by arterial aneurysms, but in VHL the central nervous
system is affected by tumors.
The tuberous sclerosis complex (TSC) should be considered in
the differential diagnosis of multiple renal tumors. In both, TSC
and VHL, multiple renal cysts occur. However, the TSC-associ-
ated renal tumor is usually an angiomyolipoma. Angiomyolipomas
are clinically characterized by an echodense appearance on sonog-
raphy and the presence of fat detectable by CT scan and MR
imaging. In TSC, extrarenal lesions, such as facial or periungual
fibroma, cranial periventricular calcifications and cortical tubera
are diagnostic for TSC [26]. Mental retardation, epilepsy, and
neuropsychiatric manifestations occur in TSC.
Clinical management
Surgery is the only accepted treatment of RCC in VHL. The
critical questions are the time of the operation and the surgical
technique. For surgery to be effective, it must be performed
before renal vein invasion and distant metastases occur. But
should small renal tumors I to 3 cm in diameter be removed? The
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Table 2. Characteristics of VHL-associated kidney lesions
answer to this question is not available yet. Previously, VHL
patients with bilateral renal tumors were treated with bilateral
nephrectomy [27—29]. Currently, nephron sparing surgery is ac-
cepted as the method of choice [13, 30—33]. Most urologists prefer
tumor resection after clamping the artery and vein and superficial
cooling using crushed ice which enables an operation time of up to
two hours. Repeated surgical procedures may be required to treat
the renal tumors that continue to develop in VHL patients [31.
Laparoscopy is just being introduced for the treatment of renal
cancers and may have a role in the management of patients with
VHL-associated RCC [34].
Bilateral nephrectomy and renal transplantation might be an
acceptable alternative to repeated nephron sparing surgeries in
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may point to ocular and central nervous system manifestations of
VHL [42, 43].
Currently, the following screening program is recommended for
a patient suspected of having VHL: Gadolinium-enhanced MRI
of the brain and spinal cord, detailed examination of the retina, a
24-hour urine collection for catecholamines, and an abdominal
CT scan. Central nervous system hemangioblastoma are best
detected with Gadolinium-enhanced MRI. Pheochromocytomas
are best detected with MRI and metaiodobenzylguanidine scm-
tigraphy (MIBG) [41]. So far, clinical studies cannot be replaced
by laboratory tests, since only 70% of VHL families have been
shown to have VHL mutations [44].
Once the diagnosis of VHL is made, other family members
must be contacted to discuss the presence of an inherited disorder
in their family and to institute effective medical management.
Knudson's two-mutation theory of cancer
Fig. 2. Asymptomatic bilateral renal cysts (C) and renal carcinoma (T) in
von Hippel-Lindau disease, abdominal CT scan at two levels (A and B) with
intravenous contrast from a 45-year-old female.
patients with VHL-associated RCC. Since the first report in 1977
[35], about 20 VHL patients have received a kidney transplant
(VHL Family Alliance, Boston, and the Freiburg VHL Register).
It is time for a careful evaluation of the prognosis of these
patients. It is not known whether the immunosuppressive drugs
required for kidney transplantation promote the growth of the
retinal and central nervous system hemangioblastomas and other
lesions found in patients with VHL.
Extrarenal VHL-associated lesions
The identification of extrarena! VHL-associated lesions (Table
1) may confirm the diagnosis of VHL in a patient with renal
lesions, suggestive of VHL. Available abdominal CT scans should
be carefully examined for the presence of pancreatic lesions (Fig.
5) and pheochromocytomas [36—40]. Up to 30% of VHL-associ-
ated pheochromocytomas have been found in the paraganglia
[411. Unilateral blindness and symptoms of cerebellar dysfunction
Knudson's two mutation theory helps us understand the patho-
genesis of von Hippel-Lindau disease (see below). Knudson's
theory of cancer has come to occupy a dominant position in
studies of the genetics of human cancer [45]. Knudson studied
retinoblastoma, a tumor of the eye that occurs in children in
sporadic and inherited forms. He determined the age of onset of
disease and the number of tumors per eye in sporadic and
inherited forms of the disease. Hereditary retinoblastomas oc-
curred at a younger age than sporadic retinoblastomas, and
tumors in patients with hereditary retinoblastoma were often
multiple. The epidemiologic data could be explained best by a two
mutation model (Fig. 6). In hereditary retinoblastoma, the first
mutation was inherited, and therefore was present in all cells of
the patient. This initial mutation was necessary but not sufficient
to produce eye tumors. A second mutation was required (after
fertilization) to trigger a cell along the path of malignant trans-
formation. The explanation for the earlier onset and multiplicity
of tumors in hereditary compared to sporadic retinoblastoma is
that after fertilization, only one mutation is necessary to trigger
tumor formation in hereditary retinoblastoma, while two muta-
tions after fertilization are required to produce sporadic retino-
blastomas. According to Knudson's theory, in order for a cell to
become transformed, the function(s) of a critical growth control
gene must be inactivated by mutations, or by epigenetic events
that affect both copies of the gene (Fig. 7). One assumption of this
model is that sporadic and inherited forms of cancer are caused by
mutation of the same genes. The model suggests that it should be
possible to use the methods of classical genetics to determine the
chromosomal location of cancer genes in families with inherited
forms of cancer, to clone these cancer genes, and then to test
these genes to determine whether they are mutated in sporadic
versions of the tumors. By studies of inherited forms of colon,
breast and kidney cancer, many of the genes responsible for these
disorders have been identified. Because normal function of these
genes is required for regulation of cell growth, these genes have
been named "tumor suppressor" genes.
Fig. 3. Asymptomatic carcinoma of the right kidney in a 36-year-old male VHL patient. Note that angiography (a) shows only one tumor, but surgery
disclosed additional small carcinomas at the upper pole (b, c - arrows).
Fig. 4. Histology of renal tumors in VHL showing clear cell carcinoma, in part solid (a) or cystic (b). Hematoxylin and eosin staining. Reproduction of
Figures 3 and 4 in color is made possible by a grant from Fresenius Medical Care, Germany.
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Table 3. Differential diagnosis of renal cysts in adulthood
Entity
Renal
characteristics Extrarenal lesions
Affected
relatives
Transmission
modc Renal function Gene
Polycystic kidney disease (P1(D)
Autosomal dominant PKD1 Innumerable
cysts
Liver cysts,
pancreas and
Parents, siblings,
children
AD Chronic renal
failure starting
# l6pl3
clonedh
Autosomal dominant PKD2 scattered all
over the
spleen cysts,
cranial
in adulthood # 4q13—23
cloned"
Autosomal dominant PKD parenchyma aneurysms
nonl-non2
Autosomal recessive PKD Periportal fibrosis Siblings AR Chronic renal
failure in
childhood or
adolescence
# ti2l
mapped'
Acquired polycystic kidney Shrunken None None End-stage renal
disease kidneys with
cysts
failure
Nephronophthisis Cysts at the
cortico-
medullary
boundary
Mostly none Siblings AR Chronic renal
failure in
adolescence
type 1 # 2q13
mappedc
type 2 not
mapped
Senior-Loken syndrome Cysts at the
cortico-
medullary
boundary
Retinitis
pigmentosa
Siblings AR Chronic renal
failure in
adolescence
not mapped
Medullary cystic disease Cysts in the
cortico-
medullary
boundary
None Parents, siblings,
children
AD Chronic renal
failure in
young
adulthood
not mapped
von Hippel-Lindau disease Cysts and
tumors
(see this article) Parents, siblings,
children
AD Normal # 3p25-26
cloned"
Tuberous sclerosis complex Angiomyolipoma, (see paragraph 5) Parents, siblings, AD Normal or late type I # 9q34
types I and 2 cysts children onset of
chronic renal
failure
mappedc
type 2 # l6pl3
cloned"
Echinococcosis Structures
within cyst
calcification
of cyst wall
Sometimes also
liver hydatides
None Normal
Simple cysts None None Normal
AD, autosomal dominant; AR, autosomal recessive
Direct genetic diagnosis in an increasing number of cases/families available
Genetic diagnosis in large families by linkage analysis with high likelihood possible
Knudson's model of carcinogenesis applied to renal cancer and
von Hippel-Lindau disease
Cytogenetic studies demonstrated that the short arm of chro-
mosome 3 (3p) was consistently deleted in sporadic renal carci-
nomas [46]. A family was identified with a constitutional (germline)
balanced translocation between the short arm of chromosome 3
and long arm of chromosome 8 [47]. This inherited translocation
segregated with a predisposition to develop renal cancer. Family
members who inherited the translocation had a 90% chance of
developing renal cancer by age 60. Family members who did not
inherit the translocation did not have an increased risk of
developing renal cancer. Both studies pointed to chromosome 3p
as the location of a gene that might be involved in the pathogen-
esis of renal carcinoma. This conclusion was supported by molec-
ular studies that demonstrated a loss of DNA sequences on
chromosome 3p in most sporadic clear cell renal carcinomas [48,
49].
To search for this RCC (renal cell carcinoma) gene required
finding families with an inherited form of renal cancer to deter-
mine the chromosomal location of the VHL gene. We were
unable to find families with "pure" inherited renal cancer, that is,
families with an inherited predisposition to develop renal cancer
without a concomitant predisposition to develop other tumors.
VHL is an inherited multisystem neoplastic disorder associated
with a predisposition to develop renal cancer as well as tumors of
the eyes, brain, spinal cord, adrenal glands and pancreas [1]. We
decided to isolate the VHL gene, suspecting that this VHL gene
might be a gene involved in the pathogenesis of sporadic kidney
cancer.
The VHL gene
The VHL gene was isolated in 1993 by the use of genetic and
physical mapping techniques [50—55]. The VHL gene is located
near the tip of chromosome 3p at 3p25 to 26. The gene encodes
a 213 amino acid protein in three exons. The gene is widely
expressed in all the tissues that have been tested by Northern
analysis. The promoter of the VHL gene has been identified; it
contained several putative transcription factor binding sites [56].
The VHL gene has a long 3' untranslated region whose function
is unknown. The VHL gene was found to be mutated in sporadic
clear cell renal carcinomas, and in the germline of patients with
VHL (see below), indicating that the gene plays an important role
p
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contact with each other, the VHL protein was located in the
nucleus.
Elongin
Fig. 5. Multiple pancreatic cysts, bilateral renal cysts and (not shown) right
kidney cancer in a 37-year-old male VHL patient.
in the pathogenesis of clear cell renal carcinoma. The VHL gene
is involved as a first event in the pathway of the renal cell to
malignancy.
The VHL protein (pVHL)
One of the major recent discoveries in VI-IL research is the
function and cellular location of the VHL protein. The function of
the VHL protein was found by identifying cellular proteins that
bound to pVHL [57—601. Two molecular weight proteins that
bound to pVHL were shown to be subunits B and C of Elongin.
Elongin is a protein that regulates the rate of transcription
elongation mediated by RNA polymerase II [61—65; see below].
The binding of Elongin B and Elongin C by pVHL was detected
by several different methods. Duan et a! and Kibel et al overex-
pressed VHL in monkey kidney cells, precipitated pVHL with
antibodies and identified proteins that bound to pVHL by SDS-
PAGE [66—69]. Kishida et a! and Kibel et a! prepared VHL fusion
proteins bound to a solid support, and used these VHL fusion
proteins to identify cellular proteins that bound to pVHL (Fig. 7).
These different experimental approaches led to the identification
of the same proteins, Elongins B and C.
Studies by Kishida and Kibel have localized the Elongin B and
C binding domain of the VHL protein to a COOH terminal
peptide [68, 69]. These workers used a panel of GST fusion
proteins that contained either the wild type, or mutant VHL
proteins. Mutant VHL proteins included recombinant VHL pro-
teins prepared with various deletions of the VHL gene, and
proteins prepared with changes in single amino acids. The amino
acid changes were selected from known naturally occurring VHL
germline missense mutations. Of particular interest, the region of
the VHL protein identified as the Elongin binding domain, has
been shown to contain a cluster of germline missense mutations in
the VHL gene. This observation suggests that the structural
integrity of this region is critical to the normal functioning of the
VHL protein.
Cellular location of pVHL
Kibel et al [69, 70] located pVHL in the cytoplasm; Duan et al
[66] demonstrated that the location of the VHL protein in cells
was dependent on cell density. When cells were in contact, the
VHL protein was located in the cytoplasm; when cells were not in
Elongin was isolated as an enzymatic activity that facilitated the
rate of transcription elongation as defined by in vitro transcription
assays. The Elongin protein is a heterotrimer, composed of a
110,000 kDa (Elongin A), a 15 kDa (Elongin B), and a 10 kDa
(Elongin C) subunits. These three subunits have been cloned
[71—77].
Transcription, the process of converting a gene's DNA se-
quence into a corresponding RNA, is a remarkably complex
biological process. Transcription can be divided into transcription
initiation, elongation and termination. Transcription initiation
requires at least six general transcription initiation factors, RNA
polymerase II and in some genes, tissue specific regulatory
proteins. After transcription has been initiated there are points
within the nucleotide sequence encoding the protein that cause
the RNA polymerase LI complex to pause during the process of
addition of RNA nucleotides to the nascent RNA chain. Elongin
facilitates the elongation of the nascent RNA chain by reducing
the pausing of the polymerase.
Elongin A is the transcriptionally active component of Elongin;
Elongin B and C are regulatory subunits. Elongin B serves a
chaperone-like function facilitating assembly and enhancing sta-
bility of the Elongin complex. Elongin C appears to function as a
direct activator of Elongin A. Elongin A and VHL compete for
binding to Elongins B and C. The presence of highly purified VHL
during assembly of the Elongin ABC complex resulted in substan-
tial inhibition of Elongin activity in both the runoff transcription
assay and the tailed-template assay. pVHL inhibits the stimulatory
effects of Elongin on transcription by binding to the Elongin B and
C subunits of the protein.
Is binding of Elongins B and C by the VHL protein the main
function of the VHL protein?
Missense mutations located outside the Elongin binding do-
main cause VHL. This observation indicates that changes in
amino acids outside the Elongin-binding domain can produce
disease, and suggest that there may be other regions of the protein
with other, as yet unknown, functions. It will be important to
evaluate a panel of mutant pVHL proteins in assays of RNA
transcription to determine whether the Elongin-binding domain
coincides with the transcription domain.
Regulation of vascular endothelial growth factor by the von
Hippel-Lindau tumor suppressor protein
The hemangioblastomas of the eye and central nervous system
found in patients with von Hippel-Lindau disease are composed
of endothelial cells and immature primitive blood vessels. These
hemangioblastomas, as well as clear cell renal carcinomas are
characterized by infiltration of the tumor with new blood vessels.
Recent studies [70, 78, 79] suggest that the basis of this angiogenic
response is the secretion of large amounts of vascular endothelial
growth factor (VEGF) by VHL tumors. Transfection of wild-type
VHL gene into renal carcinoma cells led to reduction of vascular
endothelial growth factor secretion and corrected regulation of
VEGF.
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Fig. 7. Cellular proteins that bind pVHL. 35S labeled proteins from a renal
carcinoma line (A498) were incubated with sepharose GST or sepharose
GST-VHL. Bound proteins were eluted and resolved by SDS-PAGE. The
p14 and p10 proteins are, respectively, Elongin B and Elongin C. Left
scale is in kDa.
Germline mutations in the VHL gene
In contrast to some inherited disorders in which the disease is
produced by a limited number of mutations, VHL is caused by
many different mutations. More than 140 distinct intragenic
mutations in the VHL gene have been found. Most of these
mutations were found in one to two families, suggesting that most
VHL mutations are of recent origin [44]. Founder effects are rare
in VHL. A single example of a founder effect was identified with
VHL families in the Black Forest region of Germany [801.
Germline mutations of the VHL gene can be divided into those
predicted to produce a truncated VHL proteins (deletion or
insertion of 1 to 2 nucleotides, mutations that encode a stop
codon, splice site mutations, or mutations that delete large parts
of the gene) and those predicted to produce intact VHL proteins
with a change in a single amino acid (missense mutations).
Mutations that produce truncated Vi-IL proteins produce a
disease characterized by retinal angiomas, spinal and cerebellar
hemangioblastomas, pancreatic cysts and kidney cancer (VHL
type 1). Mutations that produce intact VHL proteins with changes
in a single amino acids produce a disease characterized by
pheochromocytomas in addition to the tumors described for VHL
type 1. In a few rare instances, pheochromocytoma is the predom-
inant neoplasm, while renal carcinomas are rare or non existent
(Figs. 8 and 9).
Classification of VHL would be improved, if it was based on the
specific germline mutation present in the family. There are several
types of VHL based on the differences in cancer phenotype
produced by different germline missense mutations.
Somatic VHL mutations
As predicted by the Knudson model [81], the VHL gene is
inactivated in sporadic clear cell carcinomas of the kidney. The
VHL mutation is specific for clear cell renal carcinoma, a
particular histologic type of kidney cancer. Somatic inactivation of
the VHL gene takes place by intrageneic mutations, and in some
cases by hypermethylation of the VHL gene [82—84]. About 70 to
75% of clear cell carcinomas of the kidney show inactivation of
both copies of the VHL gene either by intragenic mutation, or by
hypermethylation of the VHL gene combined with physical loss of
the normal counterpart of the VHL gene.
The types of mutations found in the germline differ from those
found in sporadic renal tumors. Large deletions in the VHL gene
are found in 14% of VHL families; such mutations are not found
in the VHL gene in sporadic clear cell renal carcinomas. Meiotic
events may produce large deletions in the VHL gene. Somatic
mutations in VHL gene are clustered in exon 2 [85].
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Types of VHL germ line mutations
Fig. 8. Correlation between the types of germline VI-IL mutation and pheochromocytoma.
VHL Type 1 VHL Type 2A
Renal cell cancer Retinal angiomas
Pheochromocytoma CNS hemangioblastoma
Impact of molecular medicine on the diagnosis and treatment
of patients/families with von Hippel-Lindau disease
Before the advent of molecular medicine, when a diagnosis of
von Hippel-Lindau disease was made, it led to recommendations
to screen the at-risk members, such as first degree relatives, of the
family throughout their lifetimes to determine whether they had
manifestations of the disease. Asymptomatic parents, siblings and
children of affected individuals were advised to have abdominal
CT scans, spinal and brain MRI, and ophthalmologic exams once
a year for life. This recommendation imposed a considerable
burden on asymptomatic members of VHL families. The advent
of molecular medicine changes the practice of medicine for
patients with inherited forms of cancer (like VHL). Once the
germline mutation has been identified for a given family with
VHL, at-risk members of the family can be tested for the presence
of the germline mutation characteristic of their family [85]. If no
germline mutation is identified in an at-risk member of a VHL
family, it is not necessary to subject that individual to periodic
medical testing for occult manifestations of VHL. If a germline
VHL mutation is detected, that individual should be periodically
Fig. 9. Pedigrees of families with different types
of VHL. Left. Family with Von Hippel-Lindau
disease from Louisiana. Note: No family
member had pheochromocytoma. This family
had a germline deletion in the VHL gene
detected with the gp7 eDNA and is an example
of VHL type 1. Right: Family with Von Hippel-
Lindau disease from the Black Forest Area!
Germany. Note: All but one of the affected
members had pheochromocytoma. This family
had a nucleotide 505 TIC (Tyr98His) mutation
and is an example of VHL type 2A.
examined for manifestations of the disease taking the specific
mutation into account, as well as the age specific incidence of
VHL tumors.
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